A peptide agonist of GnRH
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Deslorelin (acetate)

Item No. 34041

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6-D-tryptophan-9-(N-ethyl-L-prolinamide)-1-9-luteinizing hormone-releasing factor (swine), acetate
CAS Number
1642579-30-3
Synonyms
  • D-Trp6-Pro9-des-Gly10-GnRH ethylamide
  • pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt
Molecular Formula
C64H83N17O12 • XC2H4O2
Formula Weight
1282.5
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlEthanol: 10 mg/ml
λmax
219 nm
SMILES
OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@@H](NC([C@@H](NC([C@H]2NC(CC2)=O)=O)CC3=CN=CN3)=O)CC4=CNC5=CC=CC=C45)=O)=O)C(N[C@@H](C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N6[C@@H](CCC6)C(NCC)=O)=O)=O)=O)CC7=CNC8=CC=CC=C78)=O.CC(O)=O
InChi Code
InChI=1S/C64H83N17O12.C2H4O2/c1-4-68-62(92)53-16-10-24-81(53)63(93)46(15-9-23-69-64(65)66)74-56(86)47(25-35(2)3)75-58(88)49(27-37-30-70-43-13-7-5-11-41(37)43)77-57(87)48(26-36-17-19-40(83)20-18-36)76-61(91)52(33-82)80-59(89)50(28-38-31-71-44-14-8-6-12-42(38)44)78-60(90)51(29-39-32-67-34-72-39)79-55(85)45-21-22-54(84)73-45;1-2(3)4/h5-8,11-14,17-20,30-32,34-35,45-53,70-71,82-83H,4,9-10,15-16,21-29,33H2,1-3H3,(H,67,72)(H,68,92)(H,73,84)(H,74,86)(H,75,88)(H,76,91)(H,77,87)(H,78,90)(H,79,85)(H,80,89)(H4,65,66,69);1H3,(H,3,4)/t45-,46-,47-,48-,49+,50-,51-,52-,53-;/m0./s1
InChi Key
LYCYLGFSIXIXAB-NUZRHMIVSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $121

    Add

    10 mg

    $215

    Add

    25 mg

    $448

    Add

    50 mg

    $833

    Add
    Product Description

    Deslorelin is a peptide agonist of gonadotropin-releasing hormone (GnRH).1 It binds to the GnRH receptor (GnRHR) with a Ki value of 0.1 nM. Deslorelin decreases testicular volume, semen volume, sperm motility, and total sperm count, as well as increases the percentage of abnormal sperm, in dogs when administered via a subcutaneous implant at doses of 3, 6, and 12 mg/kg.2 It decreases disease severity and plasma levels of estradiol, 17-hydroxyprogesterone, and androstenedione in ferrets with adrenocortical disease (ACD) when administered at doses ranging from 3 to 4.41 mg/kg per implant.3 Deslorelin (4.7 mg/implant per animal) suppresses ovulation and estrus in cats.4 Formulations containing deslorelin have been used in the management of ACD in ferrets and ovulation regulation and artificial insemination in horses.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Nederpelt, I., Georgi, V., Schiele, F., et al. Characterization of 12 GnRH peptide agonists - a kinetic perspective. Br. J. Pharmacol. 173(1), 128-141 (2016).

    2. Junaidi, A., Williamson, P.E., Martin, G.B., et al. Dose-response studies for pituitary and testicular function in male dogs treated with the GnRH superagonist, deslorelin. Reprod. Domest. Anim. 44(5), 725-734 (2009).

    3. Wagner, R.A., Piché, C.A., Jöchle, W., et al. Clinical and endocrine responses to treatment with deslorelin acetate implants in ferrets with adrenocortical disease. Am. J. Vet. Res. 66(5), 910-914 (2005).

    4. Ackermann, C.L., Volpato, R., Destro, F.C., et al. Ovarian activity reversibility after the use of deslorelin acetate as a short-term contraceptive in domestic queens. Theriogenology 78(4), 817-822 (2012).